penicillin-intermediate and -resistant pneumococci. 13 With the increase in resistance and the limited number of antimicrobials offering an appropriate spectrum of activity for empirical use, the need for new therapeutic agents is pressing.
Gemifloxacin is a novel quinolone antibacterial agent that is highly potent against the respiratory tract pathogens S. pneumoniae, H. influenzae and M. catarrhalis.
14 To confirm these findings among clinical isolates, and to compare the potency of gemifloxacin with that of other agents currently used in the treatment of community-acquired respiratory tract infection, the in vitro activity of these antimicrobials was determined against recent clinical isolates of S. pneumoniae, H. influenzae and M. catarrhalis and against a collection of quinolone-intermediate (ofloxacin MIC 4 mg/L) and quinolone-resistant (ofloxacin MIC у 8 mg/L) isolates of S. pneumoniae. 
Materials and methods

Isolates
Broth microdilution
Microtitre susceptibility plates, prepared by Sensititre, were used for MIC testing (AccuMed International Ltd, Westlake, OH, USA; lot numbers CMP5ASMK-8331 and -8423, and CMP4BSMK-8351 and -8451). These plates contained the following compounds in serial doubling dilu 5 cfu/mL. 18 The M. catarrhalis isolates were tested in cation-adjusted MuellerHinton broth (BBL, Cockeysville, MD, USA). For the S. pneumoniae isolates, this broth was supplemented with 5% lysed horse blood (BBL). H. influenzae isolates were tested using Haemophilus Test Medium (HTM; Dade Behring, West Sacramento, CA, USA). 19 Colony counts were performed at random to ensure the appropriate inoculum density was obtained. The Microlab AT Plus 2 (Hamilton Co., Reno, NV, USA) was used to add the inoculum to the microtitre plate. Following inoculation, the plates were covered and incubated at 35°C in ambient air for 20-24 h. A 10 L aliquot of inoculum was plated on trypticase soy agar containing 5% sheep blood to determine the purity of the final test inoculum. Chocolate agar (BBL) was used to determine the purity of H. influenzae cultures. The production of -lactamase was determined for the H. influenzae isolates using the cefinase disc test obtained from BBL.
The MIC was determined as the lowest concentration of drug that inhibited visible growth of the test isolates. For trimethoprim-sulphamethoxazole, the MIC was defined as the concentration that produced an 80-90% decrease in growth compared with the positive growth control. Individual MIC data were summarized and reported as MIC range, MIC 50 and MIC 90 .
Quality control
The following quality control organisms were included on each day of testing: Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 35218. Results for that day were only accepted if the quality control values were within the acceptable limits as established by the NCCLS. 20 Quality control limits tentatively approved by the NCCLS in January 1999, were used for gemifloxacin.
Results
The MIC distributions of gemifloxacin and the comparator agents are shown in Table I 
Discussion
In this study of a large number of bacterial respiratory pathogens, the potency of gemifloxacin was found to be equal or superior to that of the comparator agents. Gemifloxacin (MIC 90 0.03 mg/L) was four-to 256-fold more potent than the other quinolones (MIC 90 0.12-Ͼ64 mg/L) and 64-to 512-fold more potent than the non-quinolone comparators (MIC 90 2-16 mg/L) for quinolone-susceptible and -intermediate S. pneumoniae. Although the quinolones were generally highly potent against H. influenzae, gemifloxacin was the most potent compound tested against this pathogen (MIC 90 0.008 mg/L). These findings are consistent with the results of other studies, which found Numerous studies have reported on the incidence of quinolone-resistant S. pneumoniae. 3, 5, 12 Although the frequency is considered relatively low, an increase in the prevalence of these resistant isolates could potentially restrict the use of quinolones in the treatment of infections caused by this organism. As shown in this study, gemifloxacin maintains its potency against S. pneumoniae strains considered resistant to other quinolones (Table II) . The highest MIC of gemifloxacin was 0.5 mg/L for these strains, as compared with 16 mg/L of trovafloxacin and Ͼ64 mg/L of ofloxacin and ciprofloxacin. The mechanisms of resistance in these quinolone-resistant strains and the reasons for the maintained potency of gemifloxacin against S. pneumoniae are discussed by Broskey et al. 22 and Morrissey & George 23 in papers within this Supplement. The results of this study demonstrated that gemifloxacin has excellent in vitro potency against recent clinical isolates of S. pneumoniae, H. influenzae and M. catarrhalis. Of particular note was its good potency against pneumococci, including strains resistant to all other quinolones tested. These findings suggest that gemifloxacin has significant potential for use in the treatment of respiratory tract infections caused by these common pathogens.
